Home › Non-Small Cell Lung Cancer › NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria

* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
* Participants must have an unresectable/metastatic carcinoma.

Exclusion Criteria

* Participants must not have Leptomeningeal metastases.
* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
* Other protocol-defined Inclusion/Exclusion criteria apply.

About the study

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

What is being tested

• BMS-986463 (drug)

Sponsor: Bristol-Myers Squibb · Participants: 240 · Started: Sep 6, 2024

Contact the study team

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT06476808

Locations in the U.S.

Conditions

• Non-Small Cell Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.